Fulgent Genetics Stock Buy Hold or Sell Recommendation
| FLGT Stock | USD 17.05 0.20 1.19% |
Given the investment horizon of 90 days and your above-average risk tolerance, our recommendation regarding Fulgent Genetics is 'Sell'. A buy or sell recommendation is an automated directive regarding whether to purchase or sell Fulgent Genetics given historical horizon and risk tolerance. When we issue a 'buy' or 'sell' recommendation for Fulgent Genetics, the advice is generated through an automated system that utilizes algorithms and statistical models.
Check out Fulgent Genetics Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. For more information on how to buy Fulgent Stock please use our How to Invest in Fulgent Genetics guide. Note, we conduct extensive research on individual companies such as Fulgent and provide practical buy, sell, or hold advice based on investors' constraints. Fulgent Genetics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price.
Fulgent |
Execute Fulgent Genetics Buy or Sell Advice
The Fulgent recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on Fulgent Genetics. Macroaxis does not own or have any residual interests in Fulgent Genetics or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Fulgent Genetics' advice using the current market data and latest reported fundamentals.
Time Horizon
30 Days |
Risk Tolerance
I am an educated risk taker |
 |  |
Sell
Market Performance | Very Weak | Details | |
Volatility | Not too volatile | Details | |
Hype Condition | Under hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Below Average | Details | |
Economic Sensitivity | Almost neglects market trends | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Buy | Details | |
Financial Strenth (F Score) | Healthy | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Fulgent Genetics Trading Alerts and Improvement Suggestions
| Fulgent Genetics generated a negative expected return over the last 90 days | |
| The company reported the previous year's revenue of 283.47 M. Net Loss for the year was (43.82 M) with profit before overhead, payroll, taxes, and interest of 107.22 M. | |
| About 56.0% of the company shares are owned by institutional investors | |
| Latest headline from thelincolnianonline.com: Intech Investment Management LLC Increases Holdings in Fulgent Genetics, Inc. |
Fulgent Genetics Returns Distribution Density
The distribution of Fulgent Genetics' historical returns is an attempt to chart the uncertainty of Fulgent Genetics' future price movements. The chart of the probability distribution of Fulgent Genetics daily returns describes the distribution of returns around its average expected value. We use Fulgent Genetics price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Fulgent Genetics returns is essential to provide solid investment advice for Fulgent Genetics.
| Mean Return | -0.13 |
| Value At Risk | -3.8 |
| Potential Upside | 3.85 |
| Standard Deviation | 2.58 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Fulgent Genetics historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
Fulgent Stock Institutional Investors
The Fulgent Genetics' institutional investors refer to entities that pool money to purchase Fulgent Genetics' securities or originate loans. These institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds.
| Shares | |||
| Citadel Advisors Llc | 2024-12-31 | 226.6 K | |
| Northern Trust Corp | 2024-12-31 | 225.4 K | |
| Charles Schwab Investment Management Inc | 2024-12-31 | 210.2 K | |
| Amvescap Plc. | 2024-12-31 | 181.7 K | |
| Barclays Plc | 2024-12-31 | 180.4 K | |
| Jane Street Group Llc | 2024-12-31 | 170.8 K | |
| Goldman Sachs Group Inc | 2024-12-31 | 157.5 K | |
| Bank Of New York Mellon Corp | 2024-12-31 | 149.9 K | |
| Point72 Asset Management, L.p. | 2024-12-31 | 143.6 K | |
| Blackrock Inc | 2024-12-31 | 3.9 M | |
| Millennium Management Llc | 2024-12-31 | 1.5 M |
Fulgent Genetics Cash Flow Accounts
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Investments | (289.9M) | (460.9M) | (261.3M) | 38.9M | (58.4M) | (61.3M) | |
| Change In Cash | 75.5M | 77.5M | (85.4M) | 18.0M | 20.7M | 11.4M | |
| Free Cash Flow | 104.1M | 514.7M | 234.7M | 4.8M | (19.3M) | (18.3M) | |
| Depreciation | 3.0M | 11.0M | 32.7M | 26.1M | 22.2M | 23.3M | |
| Other Non Cash Items | 8.0M | 16.0M | 43.5M | 115.3M | 4.9M | 4.6M | |
| Capital Expenditures | 36.5M | 23.8M | 18.8M | 22.2M | 40.3M | 42.3M | |
| Net Income | 214.3M | 506.2M | 141.9M | (167.8M) | (43.8M) | (41.6M) | |
| End Period Cash Flow | 87.4M | 164.9M | 79.5M | 97.5M | 112.1M | 56.1M | |
| Change To Netincome | 4.2M | 8.7M | 22.9M | 75.5M | 86.8M | 91.1M | |
| Change Receivables | (2.0M) | (839K) | (178.5M) | 42.3M | 38.1M | 40.0M |
Fulgent Genetics Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Fulgent Genetics or Health Care Providers & Services sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Fulgent Genetics' price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Fulgent stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over Dow Jones | -0.15 | |
β | Beta against Dow Jones | -0.28 | |
σ | Overall volatility | 2.66 | |
Ir | Information ratio | -0.03 |
Fulgent Genetics Volatility Alert
Fulgent Genetics exhibits very low volatility with skewness of 0.07 and kurtosis of 2.75. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Fulgent Genetics' stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact Fulgent Genetics' stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different financial instruments as prices fall.Fulgent Genetics Fundamentals Vs Peers
Comparing Fulgent Genetics' fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Fulgent Genetics' direct or indirect competition across all of the common fundamentals between Fulgent Genetics and the related equities. This way, we can detect undervalued stocks with similar characteristics as Fulgent Genetics or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Fulgent Genetics' fundamental indicators could also be used in its relative valuation, which is a method of valuing Fulgent Genetics by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Fulgent Genetics to competition |
| Fundamentals | Fulgent Genetics | Peer Average |
| Return On Equity | -0.0387 | -0.31 |
| Return On Asset | -0.0376 | -0.14 |
| Profit Margin | (0.15) % | (1.27) % |
| Operating Margin | (0.21) % | (5.51) % |
| Current Valuation | 276.62 M | 16.62 B |
| Shares Outstanding | 30.87 M | 571.82 M |
| Shares Owned By Insiders | 32.75 % | 10.09 % |
| Shares Owned By Institutions | 56.50 % | 39.21 % |
| Number Of Shares Shorted | 1.3 M | 4.71 M |
| Price To Earning | 3.95 X | 28.72 X |
| Price To Book | 0.46 X | 9.51 X |
| Price To Sales | 1.86 X | 11.42 X |
| Revenue | 283.47 M | 9.43 B |
| Gross Profit | 107.22 M | 27.38 B |
| EBITDA | (73.92 M) | 3.9 B |
| Net Income | (43.82 M) | 570.98 M |
| Cash And Equivalents | 515.4 M | 2.7 B |
| Cash Per Share | 17.03 X | 5.01 X |
| Total Debt | 412 K | 5.32 B |
| Debt To Equity | 0.03 % | 48.70 % |
| Current Ratio | 5.29 X | 2.16 X |
| Book Value Per Share | 36.74 X | 1.93 K |
| Cash Flow From Operations | 21.06 M | 971.22 M |
| Short Ratio | 3.54 X | 4.00 X |
| Earnings Per Share | (1.41) X | 3.12 X |
| Price To Earnings To Growth | 1.32 X | 4.89 X |
| Target Price | 20.0 | |
| Number Of Employees | 1.31 K | 18.84 K |
| Beta | 1.54 | -0.15 |
| Market Capitalization | 526.26 M | 19.03 B |
| Total Asset | 1.22 B | 29.47 B |
| Retained Earnings | 590.47 M | 9.33 B |
| Working Capital | 280.67 M | 1.48 B |
Note: Disposition of 1636 shares by Gao Hanlin of Fulgent Genetics at 16.29 subject to Rule 16b-3 [view details]
Fulgent Genetics Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Fulgent . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
About Fulgent Genetics Buy or Sell Advice
When is the right time to buy or sell Fulgent Genetics? Buying financial instruments such as Fulgent Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
Use Investing Ideas to Build Portfolios
In addition to having Fulgent Genetics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Housewares Thematic Idea Now
Housewares
Companies making housewares accessories and providing houseware services. The Housewares theme has 48 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Housewares Theme or any other thematic opportunities.
| View All Next | Launch |
Additional Tools for Fulgent Stock Analysis
When running Fulgent Genetics' price analysis, check to measure Fulgent Genetics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Fulgent Genetics is operating at the current time. Most of Fulgent Genetics' value examination focuses on studying past and present price action to predict the probability of Fulgent Genetics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Fulgent Genetics' price. Additionally, you may evaluate how the addition of Fulgent Genetics to your portfolios can decrease your overall portfolio volatility.